Today: 29 April 2026
Browse Category

NASDAQ:QURE 24 September 2025 - 9 March 2026

Atara Biotherapeutics Stock Jumps 18% as FDA Shake-Up Puts Ebvallo Back in Focus

Atara Biotherapeutics Stock Jumps 18% as FDA Shake-Up Puts Ebvallo Back in Focus

Atara Biotherapeutics shares jumped 18% Monday after reports that FDA biologics chief Vinay Prasad will depart in April. The move follows the agency’s January rejection of Atara’s EBVALLO therapy for a rare blood cancer, which wiped out 56% of the stock’s value. Atara and partner Pierre Fabre have requested a Type A meeting with the FDA to revisit the decision. Atara ended 2025 with $8.5 million in cash.
9 March 2026
····
uniQure stock jolts higher again after FDA biologics chief set to exit

uniQure stock jolts higher again after FDA biologics chief set to exit

uniQure shares surged 34% to $14.27 in U.S. premarket trading Monday after news that FDA biologics chief Vinay Prasad will step down in April. The move follows a dispute over the agency’s demand for a new sham-surgery trial of uniQure’s Huntington’s gene therapy. The FDA has not agreed to approve the treatment based on current data. uniQure ended 2025 with $622.5 million in cash and investments.
9 March 2026
·
uniQure (QURE) Stock Jumps in Pre-Market on Dec. 16, 2025: FDA AMT-130 Uncertainty, Analyst Price Targets, and Key Catalysts Ahead

uniQure (QURE) Stock Jumps in Pre-Market on Dec. 16, 2025: FDA AMT-130 Uncertainty, Analyst Price Targets, and Key Catalysts Ahead

uniQure shares jumped about 15% to $23.50 in pre-market trading Dec. 16 after a 10% after-hours gain, despite ongoing FDA uncertainty over its Huntington’s disease gene therapy, AMT-130. The FDA told uniQure its Phase I/II data are “currently unlikely” to support a Biologics License Application, prompting the company to seek further talks in early 2026.
16 December 2025
··
UniQure’s Roller-Coaster: Gene Therapy Breakthrough, FDA Setback, and What’s Next for QURE Stock

UniQure Stock Plunges 50% on FDA Shocker – What’s Next for QURE’s Gene Therapy Ambitions?

uniQure shares plunged over 50% after the FDA said data for its Huntington’s disease gene therapy is not sufficient for approval, reversing earlier guidance. The stock dropped from about $68 to $34, wiping out roughly half its market value. Analysts called it a major regulatory setback, with some cutting price targets. Shareholder rights law firms launched investigations following the 57% one-day decline.
4 November 2025
·
UniQure’s Roller-Coaster: Gene Therapy Breakthrough, FDA Setback, and What’s Next for QURE Stock

UniQure’s Roller-Coaster: Gene Therapy Breakthrough, FDA Setback, and What’s Next for QURE Stock

UniQure shares plunged nearly 65% to $23–24 midday Nov. 3 after the FDA ruled current Huntington’s trial data insufficient for approval, erasing billions in market value. The company had raised $345 million in September at $47.50/share following a surge on positive trial results. Q2 revenue was $5.3 million, with a net loss of $37.7 million. Cash reserves rose to about $550 million after the equity raise.
3 November 2025
··
uniQure (QURE) Stock Soars on Huntington’s Breakthrough – Key Facts & 2025 Outlook

A One‑Time Brain Gene Therapy Just Slowed Huntington’s by 75%—Is This the Turning Point Families Have Waited For?

Early trial data show AMT-130 gene therapy slowed Huntington’s disease progression by 75% at 36 months in high-dose patients compared to controls. Treated participants’ neurofilament light levels dropped below baseline. The neurosurgical procedure lasts 12–20 hours. The developer plans a U.S. regulatory filing in 2026 if results hold.
26 September 2025
·
uniQure (QURE) Stock Soars on Huntington’s Breakthrough – Key Facts & 2025 Outlook

Gene Therapy Breakthrough: uniQure’s QURE Stock Skyrockets on Huntington’s Triumph

uniQure shares jumped over 150% on September 24, 2025, after its Huntington’s gene therapy slowed disease progression by 75% in a landmark trial. The company’s market value rose above $2.5 billion. uniQure plans to seek FDA approval in early 2026 and secured a $175 million credit facility to support commercialization. Cash reserves reached $377 million as of June 30, 2025.
24 September 2025
····
uniQure (QURE) Stock Soars on Huntington’s Breakthrough – Key Facts & 2025 Outlook

uniQure (QURE) Stock Soars on Huntington’s Breakthrough – Key Facts & 2025 Outlook

uniQure reported its gene therapy AMT-130 slowed Huntington’s disease progression by 75% over three years in high-dose patients. Trading in QURE shares was halted on volatility; the stock jumped from $4.45 to the mid-teens. The company secured a $175 million loan to fund AMT-130’s potential launch. Wall Street analysts rate the stock “Buy,” with targets averaging $37–$40.
24 September 2025
···

Stock Market Today

  • McDonald's Stock Falls; DCF Analysis Suggests Shares Are Overvalued by 20%
    April 29, 2026, 12:55 PM EDT. McDonald's (MCD) shares have declined 3.1% over the past week and 4.4% in 30 days, with a modest 4.9% gain over one year. Despite being a widely followed global consumer brand, recent valuation checks by Simply Wall St assign McDonald's a low value score of 2 out of 6. A key valuation tool, the Discounted Cash Flow (DCF) model, estimates McDonald's fair value per share at $242.80, implying the stock is currently overvalued by around 20.4%. The DCF method projects future free cash flows discounted back to today's dollars to estimate intrinsic value. Investors should weigh these valuation findings against the company's strong five-year return of 40.1% before reassessing their positions.

Latest article

Silicon Motion Stock Jumps After Q1 Sales Double and AI Storage Outlook Tops Estimates

Silicon Motion Stock Jumps After Q1 Sales Double and AI Storage Outlook Tops Estimates

29 April 2026
Silicon Motion reported first-quarter revenue of $342.1 million, up 105% from a year earlier, and forecast second-quarter sales above Wall Street estimates. Shares rose $45.09 to $194.27 in New York trading. The company cited strong demand for embedded storage controllers and AI-related enterprise storage. CEO Wallace Kou said its MonTitan SSD controller platform will enter volume production this quarter.
Starbucks Stock Surges After Earnings Beat Makes Niccol’s Turnaround Look Real

Starbucks Stock Surges After Earnings Beat Makes Niccol’s Turnaround Look Real

29 April 2026
Starbucks raised its fiscal 2026 outlook after global comparable store sales rose 6.2% in the second quarter, beating analyst estimates. Shares jumped about 10% to $107.03. North American operating margin fell to 9.9% from 11.6% due to higher labor and product costs. The company now expects at least 5% comparable sales growth for the year.
Teradyne Stock Slides After Record AI Quarter. The Guidance Is Why.

Teradyne Stock Slides After Record AI Quarter. The Guidance Is Why.

29 April 2026
Teradyne shares fell 16% to $319.10 Wednesday after the chip-testing company forecast lower second-quarter revenue and profit, despite posting record first-quarter sales of $1.282 billion, up 87% from a year earlier. About 70% of revenue came from AI-related demand, but management warned of “lumpy growth” due to large customer programs.
Go toTop